BBLG

Bone Biologics Corporation
CAPPED RATING

Bone Biologics Corporation (BBLG) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Momentum (D-). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.5
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -54.3%
Price Return 12M -82.7%
Catalyst Signal 0.00
Market Cap $997.1K
TTM Revenue N/A
Price / Sales N/A
ROE -47.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C+ (2.7) C (2.3) D- (0.8) C+ (2.6) C (2.2)
2026-11-10 C+ (2.5) C+ (2.7) C (2.3) F (0.7) C+ (2.6) C (2.2)
2026-11-03 C+ (2.5) C+ (2.7) C (2.3) F (0.7) C+ (2.7) C (2.2)
2026-10-27 C+ (2.5) C+ (2.6) C+ (2.5) F (0.6) C+ (2.6) C (2.2)
2026-10-20 C+ (2.5) C+ (2.6) C (2.5) F (0.6) C+ (2.6) C (2.2)
Page 1 of 4